● Completed

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Condition: Unresectable Hepatocellular Carcinoma · Sponsor: Howard S Hochster

PhasePhase 2

Planned participants6

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (7)

University of Illinois Cancer Center	Chicago, Illinois, United States	—
Indiana University Melvin and Bren Simon Comprehensive Cancer Center	Indianapolis, Indiana, United States	—
University of Nebraska Medical Center	Omaha, Nebraska, United States	—
Rutgers Cancer Institute of New Jersey	New Brunswick, New Jersey, United States	—
New York University Clinical Cancer Center	New York, New York, United States	—
DHR Health Institute for Research and Development	Edinburg, Texas, United States	—
Univeristy of Wisconsin	Madison, Wisconsin, United States	—

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →